Jump to the main content block

吳宗圃

吳宗圃(Chung-Pu Wu)

Appointment: Associate Professor

Lab:Cancer Biology Laboratory

Education:Ph.D.

University/Nation:University of Cambridge, UK

Tel: +886 3 2118800 (ext 3754)

E-mail : wuchung@mail.cgu.edu.tw

Research websitehttp://paulwea.wix.com/2014-06-13

Research interests

Multidrug resistance (MDR) caused by the overexpression of ATP-binding cassette (ABC) drug transporter ABCB1 (MDR1, P-glycoprotein) and/or ABCG2 (BCRP, MXR) is a major obstacle to successful cancer chemotherapy. Functional ABCB1 or ABCG2 confers cross-resistance to multiple drugs of differing chemical classes by actively effluxing cytotoxic drugs out of cancer cells, significantly reducing the intracellular accumulation of these drugs and resulting in MDR. Moreover, ABCB1 and ABCG2 are highly expressed in various tissues including the intestine, liver, kidney, placenta, adrenal gland and blood-brain barrier (BBB), protecting the body from xenobiotics and harmful drugs. As a result, a majority of conventional chemotherapeutic agents are affected by the transport function of ABCB1 and/or ABCG2, such as reduced oral bioavailability, distribution and elimination of these drugs. Currently, the most effective way to re-sensitize MDR cancer cells is through direct and transient inhibition of the function and/or expression of these ABC drug transporters. However, the major obstacles with using novel compounds as clinically active inhibitors are often associated with the cost and the unforeseen intrinsic toxicity of these compounds. Therefore, we are proposing an alternative approach of repositioning (drug re-purposing) FDA approved therapeutic protein kinase inhibitors (PKIs) for the purpose of re-sensitizing MDR cancer cells and improve clinical outcome in patients with ABC transporter-positive MDR cancers in future clinical practices.

 

Publications:

  1. C-P Wu*, S Lusvarghi, J-C Wang, S-H Hsiao, Y-H Huang, T-H Hung, and S.V. Ambudkar.  Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.  Molecular Pharmaceutics (2019) Jul;16(7):3040-3052. (IF = 4.396; Journal Rank in PHARMACOLOGY & PHARMACY = 39/267)
  1. S-H Hsiao, S Lusvarghi, Y-H Huang, S. V. Ambudkar, S-C Hsu, and C-P Wu*.  The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug resistant cancer cells to conventional chemotherapeutic agents.  Cancer Letters (2019) Mar; 445: 34-44. (IF = 6.508; Journal Rank in Oncology = 29/229)
  1. S-H Hsiao, M Murakami, N Yeh, Y-Q Li, T-H Hung, Y-S Wu g, S. V. Ambudkar and C-P Wu*.  The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines.  Cancer Letters (2018) Oct; 434: 81-90. (IF = 6.508; Journal Rank in Oncology = 29/229)
  1. C-P Wu*, M Murakami, S-H Hsiao, T-C Liu, N Yeh, Y-Q Li, T-H Hung, Y-S Wu, SV. Ambudkar.  SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.  Cancer Letters (2018) Oct; 433: 259-272. (IF = 6.508; Journal Rank in Oncology = 29/229)
  1. C-P Wu*, Y-J Hsieh, M Murakami, S Vahedi, S-H Hsiao, N Yeh, A-W Chou, Y-Q Li, Y-S Wu, J-S Yu and S. V. Ambudkar.  Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.  Biochemical Pharmacology (2018) Sep; 155: 316-325. (IF = 4.825; Journal Rank in PHARMACOLOGY & PHARMACY = 25/267)
  1. T-H Hung, T-T Hsieh, C-P Wu, MJ Li, YL Yeh, SF Chen.  Mammalian target of rapamycin signaling is a mechanistic link between increased endoplasmic reticulum stress and autophagy in the placentas of pregnancies complicated by growth restriction.  Placenta (2017) Dec; 60:9-20. (IF = 2.773; Journal Rank in OBSTETRICS & GYNECOLOGY = 20/83) 
  1. C-W Huang, W-C Hsieh, S-T Hsu, Y-W Lin, Y-H Chung, W-C Chang, H Chiu, YH Lin, C-P Wu, T-C Yen, F-T Huang.  The use of PET imaging for prognostic integrin α2β1 phenotyping to detect non-small cell lung cancer and monitor drug resistance responses.  Theranostics (2017) 7(16):4013-4028. (IF = 8.063; Journal Rank in MEDICINE, RESEARCH & EXPERIMENTAL = 10/136)
  1. C-P Wu*, SH Hsiao, M Murakami, M-J Lu, Y-Q Li, C-H Hsieh, S V. Ambudkar and Y-S Wu.  Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.  Cancer Letters (2017) Nov 28; 409:56-65. (IF = 6.508; Journal Rank in Oncology = 29/229)
  1. C-P Wu*, SH Hsiao, M Murakami, YJ Lu, YQ Li, YH Huang, TH Hung, S V. Ambudkar, Y-S Wu.  Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter.  Molecular Pharmaceutics (2017) Aug 7;14(8):2805-2814. (IF = 4.396; Journal Rank in PHARMACOLOGY & PHARMACY = 39/267)
  1. T-H Hung, S-F Chen, C-P Wu, M-J Li, Y-L Yeh, T-T Hsieh.  Micronized progesterone pretreatment affects the inflammatory response of human gestational tissues and the cervix to lipopolysaccharide stimulation.  Placenta (2017) Sep. 57: 1–8. (IF = 2.773; Journal Rank in OBSTETRICS & GYNECOLOGY = 20/83) 
  1. C-P Wu*, M Murakami, S-H Hsiao, A-W Chou, Y-Q Li, Y-H Huang, T-H Hung, S. V. Ambudkar.  Overexpression of ATP-binding cassette sub-family G member 2 confers resistance to phosphatidylinositol 3-kinase inhibitor PF-4989216 in cancer cells.  Molecular Pharmaceutics (2017) Jul 3; 14(7):2368-2377. (IF = 4.396; Journal Rank in PHARMACOLOGY & PHARMACY = 39/267)
  1. Y-J Lin, W-C Shyu, C-W Chang, C-C Wang, C-P Wu, H-T Lee, L-J Chen, C-H Hsieh. Tumor Hypoxia Regulates Forkhead Box C1 to Promote Lung Cancer Progression.  Theranostics. (2017) Mar 5;7(5):1177-1191. (IF = 8.063; Journal Rank in MEDICINE, RESEARCH & EXPERIMENTAL = 10/136)
  1. SH Hsiao, YJ Lu, CC Yang, WC Tuo, YQ Li, YH Huang, CH Hsieh, TH Hung, C-P Wu*.  Hernandezine, a bisbenzylisoquinoline alkaloid with selective inhibitory activity against multidrug resistance-linked ATP-binding cassette drug transporter ABCB1. Journal of Natural Products (2016) Aug. 79(8): 2135-42 (IF = 4.257; Journal Rank in PLANT SCIENCES = 16/228)
  1. SH Hsiao, YJ Lu, YQ Li, YH Huang, CH Hsieh, C-P Wu*.  Osimertinib (AZD9291) attenuates the function of multidrug resistance-linked ATP-binding cassette transporter ABCB1 in vitro.  Molecular Pharmaceutics (2016) June. 13(6):2117-25. (IF = 4.396; Journal Rank in PHARMACOLOGY & PHARMACY = 39/267)
  1. C-P Wu*, YJ Hsieh, SH Hsiao, CY Su, YQ Li, YH Huang, CW Huang, CH Hsieh, JS Yu, YS Wu.  Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.  Molecular Pharmaceutics (2016). March. 13(3): 784-94. (IF = 4.396; Journal Rank in PHARMACOLOGY & PHARMACY = 39/267)
  1. J-P Gillet, JB. Andersen, JP. Madigan, S Varma, RK. Bagni, K Powell, WE. Burgan, C-P Wu, AM Calcagno, SV. Ambudkar, SS. Thorgeirsson, MM. Gottesman.  A gene expression signature associated with overall survival in patients with hepatocellular carcinoma suggests a new treatment strategy.  Molecular Pharmacology (2016) Feb. 89(2)263-72. (IF = 3.853; Journal Rank in PHARMACOLOGY & PHARMACY = 58/267)
  1. WL Chen, CC Wang, YJ Lin, C-P Wu, CH Hsieh.  Cycling hypoxia induces chemoresistance through the activation of reactive oxygen species-mediated B-cell lymphoma extra-long pathway in glioblastoma multiforme.  Journal of Translational Medicine (2015) Dec 28;13(1):389. (IF = 4.098; Journal Rank in MEDICINE, RESEARCH & EXPERIMENTAL = 41/136)
  1. C-P Wu*, C-H Hsieh, S-H Hsiao, S-Y Luo, C-Y Su, Y-Q Li, Y-H Huang, C-W Huang and S-C Hsu.  Human ATP-binding cassette transporter ABCB1 confers resistance to volasertib (BI 6727), a selective inhibitor of polo-Like kinase 1.  Molecular Pharmaceutics (2015) Nov, 12(11): 3885-95. (IF = 4.396; Journal Rank in PHARMACOLOGY & PHARMACY = 39/267)
  1. C-H Hsieh, Y-J Lin, C-P Wu, H-T Lee, W-C Shyu and C-C Wang. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.  Clinical Cancer Research (2015) Jan, 21(2): 460-70. (IF = 8.911; Journal Rank in ONCOLOGY = 16/229)
  1. C-P Wu*, S-H Hsiao, C-Y Su, S-Y Luo, Y-Q Li, Y-H Huang, C-H Hsieh and C-W Huang.  Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2. Biochemical Pharmacology (2014) Nov, 92: 567-576. (IF = 4.825; Journal Rank in PHARMACOLOGY & PHARMACY = 25/267)
  1. C-P Wu*, S-H Hsiao, S-Y Luo, W-C Tuo, C-Y Su, Y-Q Li, Y-H Huang and C-H Hsieh.  Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1.  Molecular Pharmaceutics (2014) Oct, 11(10): 3727-36. (IF = 4.396; Journal Rank in PHARMACOLOGY & PHARMACY = 39/267)
  1. C-P Wu, SV Ambudkar.  The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy.  Acta Pharm Sin B. (2014) Apr;4(2):105-11. (IF = 5.808; Journal Rank in PHARMACOLOGY & PHARMACY = 17/267) 

 

Click Num: